fda panel nixes two 'hot flash' drugs 
medpage today fda panel nixes two 'hot flash' drugs gillen quoted 
school
bren
ics
mission
dean's
welcome
bren
gift
donald
bren
hall
visit
bren
school
contact
us
equity
diversity
departments
computer
science
informatics
statistics
research
research
areas
research
centers
research
highlights
education
graduate
apply
degrees
tuition
costs
courses
faq
research
areas
policies
forms
contact
counselor
graduate
housing
computing
support
visit
bren
school
undergraduate
computing
support
computer
lab
information
contact
counselor
course
listings
degrees
faq
financial
aid
honors
program
housing
ics
jobs
mentor
program
policies
recently
admitted
student
council
student
life
student
resources
tuition
costs
prospective
undergrad
uci
parents
people
faculty
staff
graduate
students
community
alumni
friends
parent
programs
leadership
council
make
gift
news
get
involved
tech
talks
information
sessions
sponsor
projects
leadership
council
corporate
partners
sponsor
interns
icsjobs
butterworth
competition
bren
school
home
community
news
articles
march
4
2013medpage
todayfda
panel
nixes
two
'hot
flash'
drugsby
david
pittman
read
story
view
medpage
today
website
fda
advisory
committee
voted
approving
two
medications
aimed
becoming
first
nonhormonal
products
treat
hot
flashes
associated
menopause
agreeing
neither
drug
effective
purpose
agency's
reproductive
health
drugs
advisory
committee
monday
voted
4
10
recommending
approval
paroxetine
mesylate
panelists
voiced
concern
lack
difference
frequency
hot
flashes
women
placebo
treatment
arms
paroxetine
lowered
frequency
hot
flashes
per
day
0
9
1
7
12
weeks
two
randomized
controlled
trials
committee
members
feel
difference
great
enough
warrant
approval
also
compared
4
weeks
treatment
treatment
effect
diminished
one
fourth
one
study
maintained
second
study
12
weeks
drug
nonhormonal
therapy
placebo
effect
going
strong
going
difficult
agent
meet
criteria
clifford
rosen
md
maine
medical
center
research
institute
scarborough
said
daniel
gillen
phd
statistics
professor
university
california
irvine
noted
difficult
lend
support
product
one
trial
lowered
number
hot
flashes
per
day
5
9
12
weeks
patients
taking
placebo
trial
reported
5
0
fewer
hot
flashes
per
day
tablets
containing
paroxetine
mesylate
selective
serotonin
reuptake
inhibitor
ssri
first
approved
2003
pexeva
treat
depression
obsessive
compulsive
disorder
panic
disorder
generalized
anxiety
disorder
manufacturer
new
york
city's
noven
therapeutics
yet
give
trade
name
new
potential
indication
drug
taken
daily
evening
dosages
psychiatric
indications
start
10
mg
drugmaker
trying
gain
additional
indication
lower
dose
7
5
mg
currently
marketed
panel
members
also
voiced
concern
rise
suicidality
agency
found
ssris
overall
incidence
adverse
events
differ
much
treatment
arms
fda
said
earlier
day
committee
members
voiced
many
concerns
gabapentin
tablets
sefelsa
voting
2
12
recommending
approval
drug
failed
reduce
severity
frequency
hot
flashes
statistically
significant
levels
12
weeks
three
phase
iii
trials
fda
said
patients
gabapentin
experience
1
5
1
6
fewer
hot
flashes
per
day
patients
placebo
4
weeks
three
randomized
blinded
placebo
controlled
trials
nearly
1
700
postmenopausal
women
revealed
results
statistically
significant
committee
members
voted
1
13
supporting
efficacy
data
panelists
expressed
concern
large
treatment
effect
placebo
arm
narrow
benefit
treatment
showed
risk
medication
ignored
treatment
moderate
effectiveness
chair
julia
johnson
md
chair
obstetrics
gynecology
university
massachusetts
medical
school
worcester
said
expressing
concern
five
cancers
fda
noted
occurred
gabapentin
studies
occurred
treatment
arms
others
noted
duration
trial
12
weeks
long
enough
test
patients
likely
taking
drug
long
term
feel
severity
data
mind
outweighs
frequency
data
said
linda
keyes
phd
patient
representative
davis
calif
find
data
convincing
severity
hot
flashes
dropped
0
20
0
29
0
18
12
weeks
compared
placebo
ad
hoc
3
point
scale
severity
0
047
0
003
gabapentin
already
commonly
used
label
treat
vasomotor
symptoms
fda
said
number
drugs
approved
treatment
menopausal
symptoms
many
products
also
used
label
treat
vasomotor
symptoms
depomed
said
roughly
2
5
million
prescriptions
written
every
year
gabapentin
label
uses
tablet
form
gabapentin
already
approved
2011
gralise
treatment
post
herpetic
neuralgia
dosed
1
800
mg
daily
evening
meal
sefelsa's
manufacturer
menlo
park
calif
based
depomed
proposing
dose
600
mg
morning
meal
1
200
mg
evening
meal
fda
due
render
decision
gabapentin
may
31
noven's
paroxetine
mesylate
june
28
agency
obligated
follow
advice
advisory
committees
usually
community
alumnifriendsparentsleadership
councilnewsgive
gift
news
events
press
releases
newsnoteworthy
achievements
video
highlightsspotlightnews
magazine
calendar
events
noteworthy
archive
200920082007200620052004
copyright
inquiries
uci
directory
intranet
icswebmaster
updated
october
18
2012
